$50MSeries A, 3 March 2026
Launched with first patients dosed in a Phase 1/2 study of PRO-203.
- Amount
- $50M
- Stage
- Series A
- Announced
- 3 March 2026
- Lead
- RTW Investments
- Use of funds
- Launched with first patients dosed in a Phase 1/2 study of PRO-203.
- Checked
- Announced by the company
- Sources
- Prolium Bioscience raises $50M Series A financialcontent.com
Prolium Bioscience raises $50M Series A finsmes.com